Date | Price Target | Rating | Analyst |
---|---|---|---|
4/23/2024 | $48.00 | Buy | Truist |
2/15/2024 | $42.00 | Outperform | Wolfe Research |
12/8/2023 | $55.00 | Overweight | Wells Fargo |
11/20/2023 | $36.00 | Overweight | JP Morgan |
7/26/2023 | $50.00 | Buy | Guggenheim |
12/9/2022 | $28.00 | Buy | Mizuho |
12/7/2022 | $37.00 | Overweight | Barclays |
11/18/2022 | $39.00 | Buy | BofA Securities |
BRIDGEWATER, N.J., July 29, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2024 financial results on Thursday, August 8, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 8, 2024, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcas
BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP). Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.S.) and (646) 307-1963 (international) and referencing access code 7504027. The call will also be webcast live on the Compa
—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance on Multiple Secondary Endpoints for Both Dosage Strengths Versus Placebo— —Brensocatib Well-Tolerated at Both Dosage Strengths— —Results from ASPEN Validate DPP1 Inhibition as New Mechanism of Action with Potential to Address Range of Neutrophil-Mediated Diseases— —Insmed Plans to Advance Quickly Toward U.S. Regulatory Filing, with Anticipated U.S. Launch in Mid-2025, Pending Approval— —Insmed to Host Investor Call at 8:00 a
Truist initiated coverage of Insmed with a rating of Buy and set a new price target of $48.00
Wolfe Research initiated coverage of Insmed with a rating of Outperform and set a new price target of $42.00
Wells Fargo initiated coverage of Insmed with a rating of Overweight and set a new price target of $55.00
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 4.66% on an annualized basis producing an average annual return of 15.55%. Currently, Insmed has a market capitalization of $12.25 billion. Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $423.45 today based on a price of $75.12 for INSM at the time of writing. Insmed's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed b
Insmed's (NYSE:INSM) short percent of float has risen 10.99% since its last report. The company recently reported that it has 12.83 million shares sold short, which is 7.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.84 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Rivian Automotive Inc (NASDAQ:RIVN) stock gained 21.37% in the last week following recent CPI Data. Additionally, the Department of Energy disclosed a $1.7 billion investment to transform 11 auto facilities that are either shut down or at risk into electric vehicle manufacturing plants and supply chain hubs. Enphase Energy Inc (NASDAQ:EMPH) stock upped 21.15% after the company announced residential and commercial products that can help solar projects qualify for the “Domestic Content Bonus Credit.” D.R. Horton, Inc. (NYSE:DHI) stock rocketed 12.53%. Shares of homebuilders, building com
8-K - INSMED Inc (0001104506) (Filer)
10-Q - INSMED Inc (0001104506) (Filer)
8-K - INSMED Inc (0001104506) (Filer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection Agreed Upon with U.S. FDA— —Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J., Aug. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first globa
BRIDGEWATER, N.J., Aug. 2, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 97 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on August 1, 2024 to purchase an aggregate 133,130 shares of Insmed common stock at an exercise price of $75.33 per share, the closing trad
BRIDGEWATER, N.J., July 29, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2024 financial results on Thursday, August 8, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 8, 2024, to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcas
BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti
Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling
Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling